April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
2 citations
,
April 2018 in “Journal of Investigative Dermatology” Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.
Combining PRP with Tressfix Serum is more effective for hair regrowth in telogen effluvium than using either alone.
355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology”
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
1 citations
,
September 2025 in “Wound Repair and Regeneration” Tilapia skin matrix effectively aids skin wound healing and is a promising option for clinical use.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
October 2020 in “Der Hautarzt” Tofacitinib helped regrow hair in a woman with alopecia areata.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” D-OCT shows increased blood vessel growth in response to tissue damage in Frontal Fibrosing Alopecia and is useful for diagnosis and monitoring.
3 citations
,
July 2025 in “International Immunopharmacology”
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
2 citations
,
October 2021 in “Experimental Cell Research” Injectable platelet-rich fibrin helps hair growth by boosting key cell functions.
5 citations
,
June 2019 in “Open Forum Infectious Diseases” Six African American women experienced hair loss after switching to a new HIV medication.
18 citations
,
January 2019 in “International journal of trichology” The treatment improved hair growth in three patients with alopecia.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
16 citations
,
July 2018 in “Dermatologic Surgery” iL-PRF treatment improves hair growth for androgenetic alopecia.
June 2025 in “Indus journal of bioscience research.” Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
37 citations
,
November 2007 in “Journal of Biological Chemistry” Ku80 is a key receptor for Thymosin β4, affecting cell migration and wound healing.
April 2019 in “Journal of Investigative Dermatology” Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.
December 2025 in “Aesthetic Cosmetology and Medicine” Injectable platelet-rich fibrin therapy improved hair and scalp conditions in women with excessive hair loss.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.